Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Adaptimmune Therapeutics PLC - - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
ADAP
Nasdaq
8731
https://www.adaptimmune.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Adaptimmune Therapeutics PLC -
Adaptimmune (ADAP) Down on End of Collaboration With Roche
- Apr 15th, 2024 6:12 pm
Strategic Collaboration between Adaptimmune and Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies Terminated
- Apr 12th, 2024 12:00 pm
Roche, Adaptimmune part ways on cell therapy research
- Apr 12th, 2024 9:37 am
Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
- Mar 27th, 2024 11:30 pm
Adaptimmune Therapeutics Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
- Mar 8th, 2024 10:10 am
Adaptimmune Therapeutics PLC Reports Q4 and Full Year 2023 Financial Results
- Mar 7th, 2024 6:42 pm
Adaptimmune Therapeutics plc (NASDAQ:ADAP) Q4 2023 Earnings Call Transcript
- Mar 7th, 2024 1:24 pm
Adaptimmune Reports Q4/Full Year 2023 Financial Results and Business Updates
- Mar 6th, 2024 12:00 pm
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company's Sarcoma Franchise
- Feb 27th, 2024 1:00 pm
Adaptimmune to Report Q4 and Full Year 2023 Financial and Business Updates on Wednesday, March 6, 2024
- Feb 21st, 2024 9:00 pm
15 Top Performing European Stocks So Far in 2024
- Feb 16th, 2024 8:57 am
Adaptimmune Therapeutics PLC (ADAP) Stock Moves -1.24%: What You Should Know
- Feb 13th, 2024 11:15 pm
Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel for the Treatment of Advanced Synovial Sarcoma with Priority Review
- Jan 31st, 2024 9:44 pm
Baillie Gifford Increases Stake in Adaptimmune Therapeutics PLC
- Jan 30th, 2024 6:02 pm
Adaptimmune Therapeutics (NASDAQ:ADAP shareholders incur further losses as stock declines 22% this week, taking three-year losses to 88%
- Jan 17th, 2024 10:23 am
Adaptimmune (ADAP) Surges More Than 80% in a Month: Here's Why
- Jan 16th, 2024 4:17 pm
Adaptimmune Projects Sarcoma Franchise to Deliver US Peak Year Sales up to $400 Million - Presentation at JP Morgan Healthcare Conference
- Jan 4th, 2024 12:37 pm
Positive week for Adaptimmune Therapeutics plc (NASDAQ:ADAP) institutional investors who lost 68% over the past year
- Dec 7th, 2023 10:10 am
Adaptimmune Completes Submission of Rolling Biologics License Application (BLA) to U.S. FDA for Afami-cel for the Treatment of Advanced Synovial Sarcoma
- Dec 6th, 2023 12:00 pm
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
- Nov 30th, 2023 3:52 pm
Scroll